A Phase 3 interventional study of Peginterferon alfa-2a and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 67 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-04.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 23rd largest by enrollment, is one of 12 that started in 2003, is one of 19 in phase 3, and was the 74th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 12 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 272 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 21st largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2003, is one of 9 in phase 3, and was the 72nd registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, non-randomized, single arm study will provide treatment or re-treatment with Pegasys (peginterferon alfa-2a) as monotherapy or in combination with Copegus (ribavirin) to patients with chronic hepatitis C infection. Patients who have received prior Pegasys monotherapy or combination therapy or who were considered eligible for treatment with Pegasys in previous donor protocols will be eligible to participate in this study. Treatment will be on investigator's decision according to the approved label for up to 48 weeks, with a 24-week safety follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The treating investigator decided the most appropriate treatment. It was recommended that participants receive combination therapy.
Drug: Peginterferon alfa-2a · Drug: Ribavirin
Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
Also known as: Pegasys
For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing \< 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
Also known as: Copegus
Percentage of Participants With at Least 1 Adverse Event
Time frame: From Baseline to the end of the study (up to 72 weeks)
| Milestone | Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin |
|---|---|
| Started | 272 |
| Completed | 168 |
| Not completed | 104 |
| Withdrew: Abnormal laboratory test | 1 |
| Withdrew: Adverse event/intercurrent illness | 3 |
| Withdrew: Death | 1 |
| Withdrew: Failure to return | 43 |
| Withdrew: Insufficient therapeutic response | 22 |
| Withdrew: Refusal of treatment | 1 |
| Withdrew: Other protocol violation | 1 |
| Withdrew: Withdrawal of consent | 16 |
| Withdrew: Administrative/other | 16 |
| Percentage of participants | Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin |
|---|---|
| Percentage of Participants With at Least 1 Adverse Event | 38.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin | — | 17/272 (6.3%) | 39/272 (14.3%) |
| Event | Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin |
|---|---|
| AnemiaBlood and lymphatic system disorders | 2/272 |
| Angina pectorisCardiac disorders | 1/272 |
| PalpitationsCardiac disorders | 1/272 |
| Amaurosis fugaxEye disorders | 1/272 |
| CholecystitisHepatobiliary disorders | 1/272 |
| CholelithiasisHepatobiliary disorders | 1/272 |
| CellulitisInfections and infestations | 1/272 |
| Cryptosporidiosis infectionInfections and infestations | 1/272 |
| GastroenteritisInfections and infestations | 1/272 |
| ContusionInjury, poisoning and procedural complications | 1/272 |
| Event | Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 22/272 |
| AnaemiaBlood and lymphatic system disorders | 21/272 |
| Age Continuous(years) | Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin |
|---|---|
| Mean | 48.3 ± 9.50 |
| Sex: Female, Male(Participants) | Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin |
|---|---|
| Female | 90 |
| Male | 182 |
| Race/Ethnicity, Customized(Participants) | Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin |
|---|---|
| Black | 24 |
| Caucasian | 189 |
| Oriental | 6 |
| Other | 53 |
| Height(Centimeters (cm)) | Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin |
|---|---|
| Mean | 172.4 ± 10.22 |
| Weight(Kilograms (kg)) | Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin |
|---|---|
| Mean | 85.72 ± 19.803 |
| Body Mass Index (BMI)(kg/m^2) | Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin |
|---|---|
| Mean | 28.8 ± 5.89 |
The record gives a start of Sep 2003, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin